Mathematical models of the epidemiology and control of drug-resistant TB. (Q37754966)

22 August 2017

Mathematical models of the epidemiology and control of drug-resistant TB. (English)

1 reference

22 August 2017

1 reference

1 reference

Brian Williams

4

0 references

Christopher Dye

series ordinal

2

object named as

Christopher Dye

1 reference

22 August 2017

3

Caroline Colijn

1 reference

22 August 2017

Ted Cohen

1

1 reference

PubMed ID

20477283

22 August 2017

Megan Murray

series ordinal

5

1 reference

PubMed ID

20477283

22 August 2017

language of work or name

1 reference

1 February 2009

1 reference

Expert Review of Respiratory Medicine

22 August 2017

1 reference

22 August 2017

3

1 reference

22 August 2017

67-79

1 reference

22 August 2017

1

1 reference

Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa

22 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Worldwide emergence of extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The intrinsic transmission dynamics of tuberculosis epidemics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Control strategies for tuberculosis epidemics: new models for old problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Modeling the impact of global tuberculosis control strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Will tuberculosis become resistant to all antibiotics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

DnaE2 polymerase contributes to in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The Beijing genotype and drug resistant tuberculosis in the Aral Sea region of Central Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

High incidence of the Beijing genotype among multidrug-resistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Within-host population dynamics of antibiotic-resistant M. tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Dynamics of co-infection with M. Tuberculosis and HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Sensitivity to anti-tuberculosis drugs in HIV-positive and -negative patients in Addis Ababa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Understanding, predicting and controlling the emergence of drug-resistant tuberculosis: a theoretical framework

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Criteria for the control of drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

To treat or not to treat: the case of tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Modeling the emergence of the 'hot zones': tuberculosis and the amplification dynamics of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The competitive cost of antibiotic resistance in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Impact of bacterial genetics on the transmission of isoniazid-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The effect of drug resistance on the fitness of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The biological cost of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Does DOTS work in populations with drug-resistant tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Antituberculosis drug resistance in the south of Vietnam: prevalence and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

A likelihood-based method for real-time estimation of the serial interval and reproductive number of an epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Methodological problems in the molecular epidemiology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Sampling bias in the molecular epidemiology of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

HIV infection and multidrug-resistant tuberculosis: the perfect storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Underreported threat of multidrug-resistant tuberculosis in Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Tuberculosis epidemics driven by HIV: is prevention better than cure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The impact of HIV/AIDS on the control of tuberculosis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Modeling the joint epidemics of TB and HIV in a South African township

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of Mycobacterium tuberculosis W-Beijing family in St. Petersburg, Russia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Hospital outbreak of multidrug-resistant Mycobacterium tuberculosis infections. Factors in transmission to staff and HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Multidrug-resistant tuberculosis outbreak among US-bound Hmong refugees, Thailand, 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Molecular epidemiology of tuberculosis: current insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Variable host-pathogen compatibility in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

A new evolutionary scenario for the Mycobacterium tuberculosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Global phylogeny of Mycobacterium tuberculosis based on single nucleotide polymorphism (SNP) analysis: insights into tuberculosis evolution, phylogenetic accuracy of other DNA fingerprinting systems, and recommendations for a minimal standard SNP se

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Relationship between Mycobacterium tuberculosis genotype and the clinical phenotype of pulmonary and meningeal tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

A recently evolved sublineage of the Mycobacterium tuberculosis Beijing strain family is associated with an increased ability to spread and cause disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Global phylogeography of Mycobacterium tuberculosis and implications for tuberculosis product development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Evidence that the spread of Mycobacterium tuberculosis strains with the Beijing genotype is human population dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Strain-specific mycobacterial lipids and the stimulation of protective immunity to tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Latent coinfection and the maintenance of strain diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

WHO's new Stop TB Strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Cost-effectiveness of treating multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Cost effectiveness analysis of strategies for tuberculosis control in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

The transmission and control of XDR TB in South Africa: an operations research and mathematical modelling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Can DOTS control multidrug-resistant tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Tuberculosis models with fast and slow dynamics: the role of close and casual contacts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Transmission and Dynamics of Tuberculosis on Generalized Households

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Impact of an effective multidrug-resistant tuberculosis control programme in the setting of an immature HIV epidemic: system dynamics simulation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Impact of joined-up HIV harm reduction and multidrug resistant tuberculosis control programmes in Estonia: System dynamics simulation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Microscopic-observation drug-susceptibility assay for the diagnosis of TB

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Randomized trials to optimize treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Tuberculosis drug development pipeline: progress and hope.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Prospects for advancing tuberculosis control efforts through novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Tuberculosis control and molecular epidemiology in a South African gold-mining community

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Classification of drug-resistant tuberculosis in an epidemic area

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Variation of the expression ofMycobacterium tuberculosis ppe44gene among clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Drug resistance in tuberculosis—a reinfection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

Transmission of Tuberculosis in New York City -- An Analysis by DNA Fingerprinting and Conventional Epidemiologic Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.3.1.67

21 January 2018

Identifiers

DOI

10.1586/17476348.3.1.67

1 reference

22 August 2017

1 reference

PubMed ID

20477283